<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240408041129&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240408041129&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Mon, 08 Apr 2024 08:11:32 +0000</lastbuilddate>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583160/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Apr 1:S0735-1097(24)00940-9. doi: 10.1016/j.jacc.2024.03.368. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583160/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583160</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.368>10.1016/j.jacc.2024.03.368</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583160</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Abdul Mannan Khan Minhas</dc:creator>
<dc:creator>Roy O Mathew</dc:creator>
<dc:creator>Laurence S Sperling</dc:creator>
<dc:creator>Vijay Nambi</dc:creator>
<dc:creator>Salim S Virani</dc:creator>
<dc:creator>Sankar D Navaneethan</dc:creator>
<dc:creator>Michael D Shapiro</dc:creator>
<dc:creator>Dmitry Abramov</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Prevalence of the Cardiovascular-Kidney-Metabolic Syndrome in the United States</dc:title>
<dc:identifier>pmid:38583160</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.368</dc:identifier>
</item>
<item>
<title>Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583147/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069624. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: PRO-HF was an open-label, parallel, patient-level randomized clinical trial of routine PRO assessment or usual care at an academic HF clinic between August 30, 2021, and June 30, 2022, with 1 year of follow-up. In the PRO assessment arm, participants completed the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) at each HF clinic visit and results were shared with their treating clinician. The usual care arm completed the KCCQ-12 at randomization and 1 year later, which was not shared with the treating clinician. The primary outcome was the KCCQ-12 Overall Summary Score (OSS) between 12-15 months post-randomization. Secondary outcomes included domains of the KCCQ-12, hospitalization and emergency department visit rates, HF medication therapy, clinic visit frequency, and testing rates.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Across 17 clinicians, 1,248 participants were enrolled and randomized to PRO assessment (n=624) or usual care (n=624). The median age was 63.9 (interquartile range [IQR] 51.8-72.8), 38.9% were women, and the median baseline KCCQ-12 OSS was 82.3 (IQR 58.3-94.8). Final KCCQ-12 (available in 87.9% of the PRO arm and 85.1% in usual care [p=0.16]) median OSS scores were 87.5 (IQR 68.8-96.9) in the PRO arm and 87.6 (IQR 69.7-96.9) in the usual care arm with a baseline-adjusted mean difference of 0.2 (95% CI: -1.7 to 2.0; p=0.85). The results were consistent across pre-specified subgroups. A post hoc analysis demonstrated a significant interaction with greater benefit among participants with baseline KCCQ-12 OSS scores of 60-80 but not in less or more symptomatic participants. No significant differences were found in 1-year mortality, hospitalizations, ED visits, medication therapy, clinic follow-up, or testing rates between arms.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Routine PRO assessment in HF clinic visits did not impact patient-reported quality of life or other clinical outcomes. Alternate strategies and settings for embedding PROs into routine clinical care should be tested.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583147/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583147</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069624>10.1161/CIRCULATIONAHA.124.069624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583147</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander T Sandhu</dc:creator>
<dc:creator>Jamie Calma</dc:creator>
<dc:creator>Megan Skye</dc:creator>
<dc:creator>Neil M Kalwani</dc:creator>
<dc:creator>Jimmy Zheng</dc:creator>
<dc:creator>Jessica Schirmer</dc:creator>
<dc:creator>Natasha Din</dc:creator>
<dc:creator>Cati Brown Johnson</dc:creator>
<dc:creator>Anshal Gupta</dc:creator>
<dc:creator>Roy Lan</dc:creator>
<dc:creator>Brian Yu</dc:creator>
<dc:creator>John A Spertus</dc:creator>
<dc:creator>Paul A Heidenreich</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Clinical Impact of Routine Assessment of Patient-Reported Health Status in Heart Failure Clinic</dc:title>
<dc:identifier>pmid:38583147</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069624</dc:identifier>
</item>
<item>
<title>Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583146/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this randomized trial, a remote team-based program that identifies patients with T2D and high CV or kidney risk, provides virtual education, and prescribes SGLT2i or GLP-1 RA improves GDMT. These findings support greater utilization of virtual team-based approaches to optimize chronic disease management.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Several sodium-glucose transport protein 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) reduce cardiovascular (CV) events and improve kidney outcomes in patients with type 2 diabetes (T2D); however, utilization remains low despite guideline recommendations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A randomized, remote implementation trial in the Mass General Brigham network enrolled patients with T2D at high CV and /or kidney risk. Patients eligible for, but not prescribed, SGLT2i or GLP-1 RA were randomly assigned to simultaneous virtual patient education with concurrent prescription of SGLT2i or GLP-1 RA ("simultaneous") or two months of virtual education followed by medication prescription ("education-first") delivered by a multi-disciplinary team driven by non-licensed navigators and clinical pharmacists who prescribed SGLT2i or GLP-1 RA using a standardized treatment algorithm. The primary outcome was the proportion of patients with prescriptions for either SGLT2i or GLP-1 RA by 6 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Between March 2021 and December 2022, 200 patients were randomized. Mean age was 66.5 years, 36.5% were female, 22.0% were non-White. Overall, 30.0% had cardiovascular CV disease, 5.0% had cerebrovascular disease, and 1.5% had both. Mean estimated glomerular filtration rate (eGFR) 77.9 mL/min/1.73m<sup>2</sup> and mean urine/albumin creatinine ratio (UACR) 88.6mg/g. After two months, 69/200 (34.5%) patients received a new prescription for either SGLT2i or GLP-1 RA: 53.4% of patients in the simultaneous arm vs. 8.3% of patients were in the education-first arm (p&lt;0.001). After six months, 128/200 (64.0%) received a new prescription: 69.8 % of patients in the simultaneous arm vs. 56.0% of patients in education-first (p&lt;0.001). Patient self-report of taking SGLT2i or GLP-1 RA within six months of trial entry was similarly higher in the simultaneous versus education-first arm (69 /116; 59.5% vs 37/84; 44.0%; p&lt;0.001) Median time to first prescription was 24 (IQR 13, 50) vs 85 days (IQR 65, 106), respectively (p&lt;0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this randomized trial, a remote team-based program that identifies patients with T2D and high CV or kidney risk, provides virtual education, and prescribes SGLT2i or GLP-1 RA improves GDMT. These findings support greater utilization of virtual team-based approaches to optimize chronic disease management.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583146/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583146</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069494>10.1161/CIRCULATIONAHA.124.069494</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583146</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander J Blood</dc:creator>
<dc:creator>Lee-Shing Chang</dc:creator>
<dc:creator>Shahzad Hassan</dc:creator>
<dc:creator>Jacqueline Chasse</dc:creator>
<dc:creator>Gretchen Stern</dc:creator>
<dc:creator>Daniel Gabovitch</dc:creator>
<dc:creator>David Zelle</dc:creator>
<dc:creator>Caitlin Colling</dc:creator>
<dc:creator>Samuel J Aronson</dc:creator>
<dc:creator>Christian Figueroa</dc:creator>
<dc:creator>Emma Collins</dc:creator>
<dc:creator>Ryan Ruggiero</dc:creator>
<dc:creator>Emily Zacherle</dc:creator>
<dc:creator>Josh Noone</dc:creator>
<dc:creator>Carey Robar</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Thomas A Gaziano</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Deborah J Wexler</dc:creator>
<dc:creator>Benjamin M Scirica</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial</dc:title>
<dc:identifier>pmid:38583146</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069494</dc:identifier>
</item>
<item>
<title>Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583093/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of ASCVD, diabetes, kidney function or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of CV death, particularly HF and sudden cardiac death, without a significant effect on MI in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069568. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Sodium glucose co-transporter 2 inhibitors (SGLT2i) consistently improve heart failure and kidney-related outcomes; however, effects on major adverse cardiovascular events (MACE) across different patient populations are less clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a collaborative trial-level meta-analysis from the SGLT2i meta-analysis cardio-renal trialists consortium, which includes all phase 3, placebo-controlled, outcomes trials of SGLT2i across three patient populations (diabetes at high risk for atherosclerotic cardiovascular disease [ASCVD], heart failure [HF], or chronic kidney disease [CKD]). The outcomes of interest were MACE (composite of CV death, myocardial infarction [MI], or stroke), individual components of MACE (inclusive of fatal and non-fatal events), all-cause mortality, and death subtypes. Effect estimates for SGLT2i vs. placebo were meta-analyzed across trials and examined across key subgroups (established ASCVD, prior MI, diabetes, prior HF, albuminuria, CKD stages and risk groups).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 78,607 patients across 11 trials were included: 42,568 (54.2%), 20,725 (26.4%), and 15,314 (19.5%) were included from trials of patients with diabetes at high risk for ASCVD, HF, or CKD, respectively. SGLT2i reduced the rate of MACE by 9% (HR 0.91 [95% CI 0.87-0.96], p&lt;0.0001) with a consistent effect across all three patient populations (<i>I</i><sup>2</sup>=0%) and across all key subgroups. This effect was primarily driven by a reduction in CV death (HR 0.86 [0.81-0.92], p&lt;0.0001), with no significant effect for MI in the overall population (HR 0.95 [0.87-1.04], p=0.29), and no effect on stroke (HR 0.99 [0.91-1.07], p=0.77). The benefit for CV death was driven primarily by reductions in HF death and sudden cardiac death (HR 0.68 [0.46-1.02] and HR 0.86 [0.78-0.95], respectively) and was generally consistent across subgroups, with the possible exception of being more apparent in those with albuminuria (P<sub>int</sub>=0.02).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: SGLT2i reduce the risk of MACE across a broad range of patients irrespective of ASCVD, diabetes, kidney function or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of CV death, particularly HF and sudden cardiac death, without a significant effect on MI in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583093/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583093</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069568>10.1161/CIRCULATIONAHA.124.069568</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583093</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Siddharth M Patel</dc:creator>
<dc:creator>Yu Mi Kang</dc:creator>
<dc:creator>KyungAh Im</dc:creator>
<dc:creator>Brendon L Neuen</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:creator>David Z I Cherney</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Robert A Fletcher</dc:creator>
<dc:creator>William G Herrington</dc:creator>
<dc:creator>Silvio E Inzucchi</dc:creator>
<dc:creator>Meg J Jardine</dc:creator>
<dc:creator>Kenneth W Mahaffey</dc:creator>
<dc:creator>Darren K McGuire</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Bruce Neal</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Vlado Perkovic</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Natalie Staplin</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Christoph Wanner</dc:creator>
<dc:creator>David C Wheeler</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Yujie Zhao</dc:creator>
<dc:creator>Hiddo J L Heerspink</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Stephen D Wiviott</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Sodium Glucose Co-transporter 2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis</dc:title>
<dc:identifier>pmid:38583093</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069568</dc:identifier>
</item>
<item>
<title>Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583092/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg/dL threshold of acute pancreatitis risk in most participants. Other triglyceride-related lipoprotein parameters improved. An increase in LDL-C level was observed but with no change in ApoB level and a decrease in non-HDL-C level. The safety profile was generally favorable at all doses. Additional studies will be required to determine whether...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 7. doi: 10.1001/jamacardio.2024.0959. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Severe hypertriglyceridemia (sHTG) confers increased risk of atherosclerotic cardiovascular disease (ASCVD), nonalcoholic steatohepatitis, and acute pancreatitis. Despite available treatments, persistent ASCVD and acute pancreatitis-associated morbidity from sHTG remains.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering-RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, regulator of triglyceride metabolism) levels and evaluate its effects on other lipid parameters in patients with sHTG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: The Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2) was a placebo-controlled, double-blind, dose-ranging, phase 2b randomized clinical trial enrolling adults with sHTG at 74 centers across the US, Europe, New Zealand, Australia, and Canada from May 31, 2021, to August 31, 2023. Eligible patients had fasting triglyceride levels in the range of 500 to 4000 mg/dL (to convert to millimoles per liter, multiply by 0.0113) while receiving stable lipid-lowering treatment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants received 2 subcutaneous doses of plozasiran (10, 25, or 50 mg) or matched placebo on day 1 and at week 12 and were followed up through week 48.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point evaluated the placebo-subtracted difference in means of percentage triglyceride change at week 24. Mixed-model repeated measures were used for statistical modeling.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 229 patients, 226 (mean [SD] age, 55 [11] years; 176 male [78%]) were included in the primary analysis. Baseline mean (SD) triglyceride level was 897 (625) mg/dL and plasma APOC3 level was 32 (16) mg/dL. Plozasiran induced significant dose-dependent placebo-adjusted least squares (LS)-mean reductions in triglyceride levels (primary end point) of -57% (95% CI, -71.9% to -42.1%; P &lt; .001), driven by placebo-adjusted reductions in APOC3 of -77% (95% CI, -89.1% to -65.8%; P &lt; .001) at week 24 with the highest dose. Among plozasiran-treated patients, 144 of 159 (90.6%) achieved a triglyceride level of less than 500 mg/dL. Plozasiran was associated with dose-dependent increases in low-density lipoprotein cholesterol (LDL-C) level, which was significant in patients receiving the highest dose (placebo-adjusted LS-mean increase 60% (95% CI, 31%-89%; P &lt; .001). However, apolipoprotein B (ApoB) levels did not increase, and non-high-density lipoprotein cholesterol (HDL-C) levels decreased significantly at all doses, with a placebo-adjusted change of -20% at the highest dose. There were also significant durable reductions in remnant cholesterol and ApoB48 as well as increases in HDL-C level through week 48. Adverse event rates were similar in plozasiran-treated patients vs placebo. Serious adverse events were mild to moderate, not considered treatment related, and none led to discontinuation or death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of patients with sHTG, plozasiran decreased triglyceride levels, which fell below the 500 mg/dL threshold of acute pancreatitis risk in most participants. Other triglyceride-related lipoprotein parameters improved. An increase in LDL-C level was observed but with no change in ApoB level and a decrease in non-HDL-C level. The safety profile was generally favorable at all doses. Additional studies will be required to determine whether plozasiran favorably modulates the risk of sHTG-associated complications.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04720534.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583092/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583092</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0959>10.1001/jamacardio.2024.0959</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583092</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Denes Pall</dc:creator>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Karen Modesto</dc:creator>
<dc:creator>Javier San Martin</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Christie M Ballantyne</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38583092</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0959</dc:identifier>
</item>
<item>
<title>Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583091/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: High-dose vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 7. doi: 10.1001/jamacardio.2024.0468. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: High-dose trivalent compared with standard-dose quadrivalent influenza vaccine did not significantly reduce all-cause mortality or cardiopulmonary hospitalizations in patients with high-risk cardiovascular disease in the INVESTED trial. Whether humoral immune response to influenza vaccine is associated with clinical outcomes is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To examine the antibody response to high-dose trivalent compared with standard-dose quadrivalent inactivated influenza vaccine and its associations with clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis is a prespecified analysis of the immune response substudy of the randomized, double-blind, active-controlled INVESTED trial, which was conducted at 157 sites in the United States and Canada over 3 influenza seasons between September 2016 and January 2019. Antibody titers were determined by hemagglutination inhibition assays at randomization and 4 weeks during the 2017-2018 and 2018-2019 seasons. Eligibility criteria included recent acute myocardial infarction or heart failure hospitalization and at least 1 additional risk factor. Data were analyzed from February 2023 to June 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Mean antibody titer change, seroprotection (antibody titer level ≥1:40) and seroconversion (≥4-fold increase in titer) at 4 weeks, and the association between seroconversion status and the risk for adverse clinical outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: High-dose trivalent or standard-dose quadrivalent inactivated influenza vaccine, with revaccination up to 3 seasons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Antibody data were available for 658 of 5260 randomized participants (12.5%; mean [SD] age, 66.2 [11.4] years; 507 male [77.1%], 151 female [22.9%]; 348 with heart failure [52.9%]). High-dose vaccine was associated with an increased magnitude in antibody titers for A/H1N1, A/H3N2, and B-type antigens compared with standard dose. More than 92% of all participants achieved seroprotection for each of the contained antigens, while seroconversion rates were higher in participants who received high-dose vaccine. Seroconversion for any antigen was not associated with the risk for cardiopulmonary hospitalizations or all-cause mortality (hazard ratio, 1.09; 95% CI, 0.79-1.53; P = .59), irrespective of randomized treatment (P = .38 for interaction).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: High-dose vaccine elicited a more robust humoral response in patients with heart failure or prior myocardial infarction enrolled in the INVESTED trial, with no association between seroconversion status and the risk for cardiopulmonary hospitalizations or all-cause mortality. Vaccination to prevent influenza remains critical in high-risk populations.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02787044.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583091/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583091</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0468>10.1001/jamacardio.2024.0468</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583091</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander Peikert</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>Jacob Joseph</dc:creator>
<dc:creator>Sheila M Hegde</dc:creator>
<dc:creator>KyungMann Kim</dc:creator>
<dc:creator>Lu Mao</dc:creator>
<dc:creator>Tuo Wang</dc:creator>
<dc:creator>Thomas C Havighurst</dc:creator>
<dc:creator>Michael E Farkouh</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Matthew C Tattersall</dc:creator>
<dc:creator>Lawton S Cooper</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease: A Secondary Analysis of the INVESTED Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:38583091</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0468</dc:identifier>
</item>
<item>
<title>Coronary Angiography and Bypass Surgery: born together and now going separate ways?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583087/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 7:ehae223. doi: 10.1093/eurheartj/ehae223. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583087/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583087</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae223>10.1093/eurheartj/ehae223</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583087</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary Angiography and Bypass Surgery: born together and now going separate ways?</dc:title>
<dc:identifier>pmid:38583087</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae223</dc:identifier>
</item>
<item>
<title>Coronary bypass surgery guided by computed tomography in a low-risk population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583086/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: CABG guided by CCTA is feasible and has an acceptable safety profile in a selected population of complex coronary artery disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 7:ehae199. doi: 10.1093/eurheartj/ehae199. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: In patients with three-vessel disease and/or left main disease, selecting revascularization strategy based on coronary computed tomography angiography (CCTA) has a high level of virtual agreement with treatment decisions based on invasive coronary angiography (ICA).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In this study, coronary artery bypass grafting (CABG) procedures were planned based on CCTA without knowledge of ICA. The CABG strategy was recommended by a central core laboratory assessing the anatomy and functionality of the coronary circulation. The primary feasibility endpoint was the percentage of operations performed without access to the ICA. The primary safety endpoint was graft patency on 30-day follow-up CCTA. Secondary endpoints included topographical adequacy of grafting, major adverse cardiac and cerebrovascular (MACCE), and major bleeding events at 30 days. The study was considered positive if the lower boundary of confidence intervals (CI) for feasibility was ≥75% (NCT04142021).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study enrolled 114 patients with a mean (standard deviation) anatomical SYNTAX score and Society of Thoracic Surgery score of 43.6 (15.3) and 0.81 (0.63), respectively. Unblinding ICA was required in one case yielding a feasibility of 99.1% (95% CI 95.2%-100%). The concordance and agreement in revascularization planning between the ICA- and CCTA-Heart Teams was 82.9% with a moderate kappa of 0.58 (95% CI 0.50-0.66) and between the CCTA-Heart Team and actual treatment was 83.7% with a substantial kappa of 0.61 (95% CI 0.53-0.68). The 30-day follow-up CCTA in 102 patients (91.9%) showed an anastomosis patency rate of 92.6%, whilst MACCE was 7.2% and major bleeding 2.7%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: CABG guided by CCTA is feasible and has an acceptable safety profile in a selected population of complex coronary artery disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583086/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583086</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae199>10.1093/eurheartj/ehae199</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583086</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Patrick W Serruys</dc:creator>
<dc:creator>Shigetaka Kageyama</dc:creator>
<dc:creator>Giulio Pompilio</dc:creator>
<dc:creator>Daniele Andreini</dc:creator>
<dc:creator>Gianluca Pontone</dc:creator>
<dc:creator>Saima Mushtaq</dc:creator>
<dc:creator>Mark La Meir</dc:creator>
<dc:creator>Johan De Mey</dc:creator>
<dc:creator>Kaoru Tanaka</dc:creator>
<dc:creator>Torsten Doenst</dc:creator>
<dc:creator>Ulf Teichgräber</dc:creator>
<dc:creator>Ulrich Schneider</dc:creator>
<dc:creator>John D Puskas</dc:creator>
<dc:creator>Jagat Narula</dc:creator>
<dc:creator>Himanshu Gupta</dc:creator>
<dc:creator>Vikram Agarwal</dc:creator>
<dc:creator>Jonathon Leipsic</dc:creator>
<dc:creator>Shinichiro Masuda</dc:creator>
<dc:creator>Nozomi Kotoku</dc:creator>
<dc:creator>Tsung-Ying Tsai</dc:creator>
<dc:creator>Scot Garg</dc:creator>
<dc:creator>Marie-Angele Morel</dc:creator>
<dc:creator>Yoshinobu Onuma</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Coronary bypass surgery guided by computed tomography in a low-risk population</dc:title>
<dc:identifier>pmid:38583086</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae199</dc:identifier>
</item>
<item>
<title>Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38583084/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Behaviorally-designed gamification, loss-framed financial incentives, and the combination of both increased physical activity compared with control over a 12-month intervention period, with the largest effect in gamification + financial incentives. These interventions could be a useful component of strategies to reduce cardiovascular risk in high-risk patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069531. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Physical activity is associated with a lower risk of major adverse cardiovascular events, but few individuals achieve guideline recommended levels of physical activity. Strategies informed by behavioral economics increase physical activity, but their longer-term effectiveness is uncertain. We sought to determine the effect of behaviorally-designed gamification, loss-framed financial incentives, or the combination on physical activity compared with attention control over 12-month intervention and 6-month post-intervention follow-up periods.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Between May 2019 and January 2024, participants with clinical ASCVD or 10-year risk of myocardial infarction, stroke, or cardiovascular death ≥ 7.5% by the pooled cohort equation were enrolled in a pragmatic randomized clinical trial. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were randomly assigned to control (n = 151), behaviorally-designed gamification (n = 304), loss-framed financial incentives (n = 302), or gamification + financial incentives (n = 305). The trial's primary outcome was change in mean daily steps from baseline through the 12-month intervention period.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 1062 patients (mean [SD] age 67 [8], 61% female, 31% non-white) were enrolled. Compared with controls, participants had significantly greater increases in mean daily steps from baseline during the 12-month intervention in the gamification arm (adjusted difference, 538.0; 95% CI, 186.2-889.9; <i>P</i> = 0.0027), financial incentives arm (adjusted difference, 491.8; 95% CI, 139.6-844.1; <i>P</i> = 0.0062), and gamification + financial incentives arm (adjusted difference, 868.0; 95% CI, 516.3-1219.7; <i>P</i> &lt; 0.0001). During 6-month follow-up, physical activity remained significantly greater in the gamification + financial incentives arm than in the control arm (adjusted difference, 576.2; 95% CI, 198.5-954; <i>P</i> = 0.0028) but was not significantly greater in the gamification (adjusted difference, 459.8; 95% CI, 82.0-837.6; <i>P</i> = 0.0171) or financial incentives (adjusted difference, 327.9; 95% CI, -50.2 to 706; <i>P</i> = 0.09) arms, after adjusting for multiple comparisons.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Behaviorally-designed gamification, loss-framed financial incentives, and the combination of both increased physical activity compared with control over a 12-month intervention period, with the largest effect in gamification + financial incentives. These interventions could be a useful component of strategies to reduce cardiovascular risk in high-risk patients.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38583084/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38583084</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069531>10.1161/CIRCULATIONAHA.124.069531</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38583084</guid>
<pubDate>Sun, 07 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander C Fanaroff</dc:creator>
<dc:creator>Mitesh S Patel</dc:creator>
<dc:creator>Neel Chokshi</dc:creator>
<dc:creator>Samantha Coratti</dc:creator>
<dc:creator>David Farraday</dc:creator>
<dc:creator>Laurie Norton</dc:creator>
<dc:creator>Charles Rareshide</dc:creator>
<dc:creator>Jingsan Zhu</dc:creator>
<dc:creator>Tamar Klaiman</dc:creator>
<dc:creator>Julia E Szymczak</dc:creator>
<dc:creator>Louise B Russell</dc:creator>
<dc:creator>Dylan S Small</dc:creator>
<dc:creator>Kevin G M Volpp</dc:creator>
<dc:date>2024-04-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Gamification, Financial Incentives, or Both to Increase Physical Activity Among Patients at High Risk of Cardiovascular Events: The BE ACTIVE Randomized Controlled Trial</dc:title>
<dc:identifier>pmid:38583084</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069531</dc:identifier>
</item>
<item>
<title>The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38582530/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Apr 7;45(14):1183-1187. doi: 10.1093/eurheartj/ehae197.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38582530/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38582530</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae197>10.1093/eurheartj/ehae197</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38582530</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The complex interaction between cancer, ischaemic heart disease, and heart failure, and a focus on arrhythmias including risk stratification in Brugada syndrome and leadless pacing</dc:title>
<dc:identifier>pmid:38582530</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae197</dc:identifier>
</item>
<item>
<title>A genome-wide spectrum of tandem repeat expansions in 338,963 humans</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38582080/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>The Genome Aggregation Database (gnomAD), widely recognized as the gold-standard reference map of human genetic variation, has largely overlooked tandem repeat (TR) expansions, despite the fact that TRs constitute ∼6% of our genome and are linked to over 50 human diseases. Here, we introduce the TR-gnomAD (https://wlcb.oit.uci.edu/TRgnomAD), a biobank-scale reference of 0.86 million TRs derived from 338,963 whole-genome sequencing (WGS) samples of diverse ancestries (39.5% non-European samples)....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 28:S0092-8674(24)00252-6. doi: 10.1016/j.cell.2024.03.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The Genome Aggregation Database (gnomAD), widely recognized as the gold-standard reference map of human genetic variation, has largely overlooked tandem repeat (TR) expansions, despite the fact that TRs constitute ∼6% of our genome and are linked to over 50 human diseases. Here, we introduce the TR-gnomAD (https://wlcb.oit.uci.edu/TRgnomAD), a biobank-scale reference of 0.86 million TRs derived from 338,963 whole-genome sequencing (WGS) samples of diverse ancestries (39.5% non-European samples). TR-gnomAD offers critical insights into ancestry-specific disease prevalence using disparities in TR unit number frequencies among ancestries. Moreover, TR-gnomAD is able to differentiate between common, presumably benign TR expansions, which are prevalent in TR-gnomAD, from those potentially pathogenic TR expansions, which are found more frequently in disease groups than within TR-gnomAD. Together, TR-gnomAD is an invaluable resource for researchers and physicians to interpret TR expansions in individuals with genetic diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38582080/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38582080</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.004>10.1016/j.cell.2024.03.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38582080</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Ya Cui</dc:creator>
<dc:creator>Wenbin Ye</dc:creator>
<dc:creator>Jason Sheng Li</dc:creator>
<dc:creator>Jingyi Jessica Li</dc:creator>
<dc:creator>Eric Vilain</dc:creator>
<dc:creator>Tamer Sallam</dc:creator>
<dc:creator>Wei Li</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A genome-wide spectrum of tandem repeat expansions in 338,963 humans</dc:title>
<dc:identifier>pmid:38582080</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.004</dc:identifier>
</item>
<item>
<title>Human iPSC 4R tauopathy model uncovers modifiers of tau propagation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38582079/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>Tauopathies are age-associated neurodegenerative diseases whose mechanistic underpinnings remain elusive, partially due to a lack of appropriate human models. Here, we engineered human induced pluripotent stem cell (hiPSC)-derived neuronal lines to express 4R Tau and 4R Tau carrying the P301S MAPT mutation when differentiated into neurons. 4R-P301S neurons display progressive Tau inclusions upon seeding with Tau fibrils and recapitulate features of tauopathy phenotypes including shared...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 28:S0092-8674(24)00306-4. doi: 10.1016/j.cell.2024.03.015. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Tauopathies are age-associated neurodegenerative diseases whose mechanistic underpinnings remain elusive, partially due to a lack of appropriate human models. Here, we engineered human induced pluripotent stem cell (hiPSC)-derived neuronal lines to express 4R Tau and 4R Tau carrying the P301S MAPT mutation when differentiated into neurons. 4R-P301S neurons display progressive Tau inclusions upon seeding with Tau fibrils and recapitulate features of tauopathy phenotypes including shared transcriptomic signatures, autophagic body accumulation, and reduced neuronal activity. A CRISPRi screen of genes associated with Tau pathobiology identified over 500 genetic modifiers of seeding-induced Tau propagation, including retromer VPS29 and genes in the UFMylation cascade. In progressive supranuclear palsy (PSP) and Alzheimer's Disease (AD) brains, the UFMylation cascade is altered in neurofibrillary-tangle-bearing neurons. Inhibiting the UFMylation cascade in vitro and in vivo suppressed seeding-induced Tau propagation. This model provides a robust platform to identify novel therapeutic strategies for 4R tauopathy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38582079/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38582079</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.015>10.1016/j.cell.2024.03.015</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38582079</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Celeste Parra Bravo</dc:creator>
<dc:creator>Alice Maria Giani</dc:creator>
<dc:creator>Jesus Madero Perez</dc:creator>
<dc:creator>Zeping Zhao</dc:creator>
<dc:creator>Yuansong Wan</dc:creator>
<dc:creator>Avi J Samelson</dc:creator>
<dc:creator>Man Ying Wong</dc:creator>
<dc:creator>Alessandro Evangelisti</dc:creator>
<dc:creator>Ethan Cordes</dc:creator>
<dc:creator>Li Fan</dc:creator>
<dc:creator>Pearly Ye</dc:creator>
<dc:creator>Daphne Zhu</dc:creator>
<dc:creator>Tatyana Pozner</dc:creator>
<dc:creator>Maria Mercedes</dc:creator>
<dc:creator>Tark Patel</dc:creator>
<dc:creator>Allan Yarahmady</dc:creator>
<dc:creator>Gillian K Carling</dc:creator>
<dc:creator>Fredrik H Sterky</dc:creator>
<dc:creator>Virginia M Y Lee</dc:creator>
<dc:creator>Edward B Lee</dc:creator>
<dc:creator>Michael DeTure</dc:creator>
<dc:creator>Dennis W Dickson</dc:creator>
<dc:creator>Manu Sharma</dc:creator>
<dc:creator>Sue-Ann Mok</dc:creator>
<dc:creator>Wenjie Luo</dc:creator>
<dc:creator>Mingrui Zhao</dc:creator>
<dc:creator>Martin Kampmann</dc:creator>
<dc:creator>Shiaoching Gong</dc:creator>
<dc:creator>Li Gan</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Human iPSC 4R tauopathy model uncovers modifiers of tau propagation</dc:title>
<dc:identifier>pmid:38582079</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.015</dc:identifier>
</item>
<item>
<title>A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38581644/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In this cohort study of patients without severe AS undergoing echocardiography or CMR imaging, a new AI-based video biomarker was independently associated with AS development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 6. doi: 10.1001/jamacardio.2024.0595. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Aortic stenosis (AS) is a major public health challenge with a growing therapeutic landscape, but current biomarkers do not inform personalized screening and follow-up. A video-based artificial intelligence (AI) biomarker (Digital AS Severity index [DASSi]) can detect severe AS using single-view long-axis echocardiography without Doppler characterization.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To deploy DASSi to patients with no AS or with mild or moderate AS at baseline to identify AS development and progression.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This is a cohort study that examined 2 cohorts of patients without severe AS undergoing echocardiography in the Yale New Haven Health System (YNHHS; 2015-2021) and Cedars-Sinai Medical Center (CSMC; 2018-2019). A novel computational pipeline for the cross-modal translation of DASSi into cardiac magnetic resonance (CMR) imaging was further developed in the UK Biobank. Analyses were performed between August 2023 and February 2024.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">EXPOSURE: DASSi (range, 0-1) derived from AI applied to echocardiography and CMR videos.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: Annualized change in peak aortic valve velocity (AV-Vmax) and late (>;6 months) aortic valve replacement (AVR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 12 599 participants were included in the echocardiographic study (YNHHS: n = 8798; median [IQR] age, 71 [60-80] years; 4250 [48.3%] women; median [IQR] follow-up, 4.1 [2.4-5.4] years; and CSMC: n = 3801; median [IQR] age, 67 [54-78] years; 1685 [44.3%] women; median [IQR] follow-up, 3.4 [2.8-3.9] years). Higher baseline DASSi was associated with faster progression in AV-Vmax (per 0.1 DASSi increment: YNHHS, 0.033 m/s per year [95% CI, 0.028-0.038] among 5483 participants; CSMC, 0.082 m/s per year [95% CI, 0.053-0.111] among 1292 participants), with values of 0.2 or greater associated with a 4- to 5-fold higher AVR risk than values less than 0.2 (YNHHS: 715 events; adjusted hazard ratio [HR], 4.97 [95% CI, 2.71-5.82]; CSMC: 56 events; adjusted HR, 4.04 [95% CI, 0.92-17.70]), independent of age, sex, race, ethnicity, ejection fraction, and AV-Vmax. This was reproduced across 45 474 participants (median [IQR] age, 65 [59-71] years; 23 559 [51.8%] women; median [IQR] follow-up, 2.5 [1.6-3.9] years) undergoing CMR imaging in the UK Biobank (for participants with DASSi ≥0.2 vs those with DASSi &lt;.02, adjusted HR, 11.38 [95% CI, 2.56-50.57]). Saliency maps and phenome-wide association studies supported associations with cardiac structure and function and traditional cardiovascular risk factors.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In this cohort study of patients without severe AS undergoing echocardiography or CMR imaging, a new AI-based video biomarker was independently associated with AS development and progression, enabling opportunistic risk stratification across cardiovascular imaging modalities as well as potential application on handheld devices.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38581644/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38581644</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0595>10.1001/jamacardio.2024.0595</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38581644</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Evangelos K Oikonomou</dc:creator>
<dc:creator>Gregory Holste</dc:creator>
<dc:creator>Neal Yuan</dc:creator>
<dc:creator>Andreas Coppi</dc:creator>
<dc:creator>Robert L McNamara</dc:creator>
<dc:creator>Norrisa A Haynes</dc:creator>
<dc:creator>Amit N Vora</dc:creator>
<dc:creator>Eric J Velazquez</dc:creator>
<dc:creator>Fan Li</dc:creator>
<dc:creator>Venu Menon</dc:creator>
<dc:creator>Samir R Kapadia</dc:creator>
<dc:creator>Thomas M Gill</dc:creator>
<dc:creator>Girish N Nadkarni</dc:creator>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:creator>Zhangyang Wang</dc:creator>
<dc:creator>David Ouyang</dc:creator>
<dc:creator>Rohan Khera</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>A Multimodal Video-Based AI Biomarker for Aortic Stenosis Development and Progression</dc:title>
<dc:identifier>pmid:38581644</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0595</dc:identifier>
</item>
<item>
<title>Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38581643/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: While results from time-trend studies were inconsistent, data from case-control/crossover, cohort, and self-controlled case series studies showed that use of antibiotic prophylaxis is associated with reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk, while no association was proven for those at low/unknown risk, thereby supporting current American Heart Association and European Society of Cardiology recommendations....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Apr 6. doi: 10.1001/jamacardio.2024.0873. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: The association between antibiotic prophylaxis and infective endocarditis after invasive dental procedures is still unclear. Indications for antibiotic prophylaxis were restricted by guidelines beginning in 2007.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To systematically review and analyze existing evidence on the association between antibiotic prophylaxis and infective endocarditis following invasive dental procedures.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA SOURCES: PubMed, Cochrane-CENTRAL, Scopus, Web of Science, Proquest, Embase, Dentistry and Oral Sciences Source, and ClinicalTrials.gov were systematically searched from inception to May 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">STUDY SELECTION: Studies on the association between antibiotic prophylaxis and infective endocarditis following invasive dental procedures or time-trend analyses of infective endocarditis incidence before and after current antibiotic prophylaxis guidelines were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DATA EXTRACTION AND SYNTHESIS: Study quality was evaluated using structured tools. Data were extracted by independent observers. A pooled relative risk (RR) of developing infective endocarditis following invasive dental procedures in individuals who were receiving antibiotic prophylaxis vs those who were not was computed by random-effects meta-analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The outcome of interest was the incidence of infective endocarditis following invasive dental procedures in relation to antibiotic prophylaxis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 11 217 records identified, 30 were included (1 152 345 infective endocarditis cases). Of them, 8 (including 12 substudies) were either case-control/crossover or cohort studies or self-controlled case series, while 22 were time-trend studies; all were of good quality. Eight of the 12 substudies with case-control/crossover, cohort, or self-controlled case series designs performed a formal statistical analysis; 5 supported a protective role of antibiotic prophylaxis, especially among individuals at high risk, while 3 did not. By meta-analysis, antibiotic prophylaxis was associated with a significantly lower risk of infective endocarditis after invasive dental procedures in individuals at high risk (pooled RR, 0.41; 95% CI, 0.29-0.57; P for heterogeneity = .51; I2, 0%). Nineteen of the 22 time-trend studies performed a formal pre-post statistical analysis; 9 found no significant changes in infective endocarditis incidence, 7 demonstrated a significant increase for the overall population or subpopulations (individuals at high and moderate risk, streptococcus-infective endocarditis, and viridans group streptococci-infective endocarditis), whereas 3 found a significant decrease for the overall population and among oral streptococcus-infective endocarditis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: While results from time-trend studies were inconsistent, data from case-control/crossover, cohort, and self-controlled case series studies showed that use of antibiotic prophylaxis is associated with reduced risk of infective endocarditis following invasive dental procedures in individuals at high risk, while no association was proven for those at low/unknown risk, thereby supporting current American Heart Association and European Society of Cardiology recommendations. Currently, there is insufficient data to support any benefit of antibiotic prophylaxis in individuals at moderate risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38581643/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38581643</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.0873>10.1001/jamacardio.2024.0873</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38581643</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesca Sperotto</dc:creator>
<dc:creator>Katherine France</dc:creator>
<dc:creator>Margherita Gobbo</dc:creator>
<dc:creator>Mohammed Bindakhil</dc:creator>
<dc:creator>Kununya Pimolbutr</dc:creator>
<dc:creator>Haly Holmes</dc:creator>
<dc:creator>Luis Monteiro</dc:creator>
<dc:creator>Laurel Graham</dc:creator>
<dc:creator>Catherine H L Hong</dc:creator>
<dc:creator>Thomas P Sollecito</dc:creator>
<dc:creator>Giovanni Lodi</dc:creator>
<dc:creator>Peter B Lockhart</dc:creator>
<dc:creator>Martin Thornhill</dc:creator>
<dc:creator>Pedro Diz Dios</dc:creator>
<dc:creator>Federica Turati</dc:creator>
<dc:creator>Valeria Edefonti</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Antibiotic Prophylaxis and Infective Endocarditis Incidence Following Invasive Dental Procedures: A Systematic Review and Meta-Analysis</dc:title>
<dc:identifier>pmid:38581643</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.0873</dc:identifier>
</item>
<item>
<title>Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38581406/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.123.067691. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38581406/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38581406</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067691>10.1161/CIRCULATIONAHA.123.067691</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38581406</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Leslie Cho</dc:creator>
<dc:creator>Jorge Plutzky</dc:creator>
<dc:creator>Danielle Brennan</dc:creator>
<dc:creator>Michael J Louie</dc:creator>
<dc:creator>Lei Lei</dc:creator>
<dc:creator>Paula Robinson</dc:creator>
<dc:creator>Heather A Powell</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Impact of Bempedoic Acid on Cardiovascular Outcomes by Sex</dc:title>
<dc:identifier>pmid:38581406</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067691</dc:identifier>
</item>
<item>
<title>Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38581389/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In patients after acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduced the risk of heart failure.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Apr 6. doi: 10.1161/CIRCULATIONAHA.124.069217. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Empagliflozin reduces the risk of heart failure events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, and in those with prevalent heart failure irrespective of ejection fraction. While EMPACT-MI showed empagliflozin does not reduce the risk of the composite of hospitalization of heart failure and all-cause mortality, the impact of empagliflozin on first and recurrent heart failure events in patients after myocardial infarction is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for heart failure based on newly developed left ventricular ejection fraction of &lt;45% and/or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for heart failure outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median of follow-up of 17.9 months, the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 (3.6%) vs. 153 (4.7%) patients with events, HR 0.77 [95% CI 0.60, 0.98], P=0.031 for first heart failure hospitalization and 148 vs. 207 events, RR 0.67 [95% CI 0.51, 0.89], P=0.006 for total heart failure hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total heart failure hospitalizations. Post-discharge need for new use of diuretics, renin-angiotensin modulators, and mineralocorticoid receptor antagonists were less in patients randomized to empagliflozin than placebo (all p&lt;0.05).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In patients after acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduced the risk of heart failure.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38581389/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38581389</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.069217>10.1161/CIRCULATIONAHA.124.069217</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38581389</guid>
<pubDate>Sat, 06 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>W Schuyler Jones</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Mark C Petrie</dc:creator>
<dc:creator>Josephine Harrington</dc:creator>
<dc:creator>Michaela Mattheus</dc:creator>
<dc:creator>Svenja Seide</dc:creator>
<dc:creator>Isabella Zwiener</dc:creator>
<dc:creator>Offer Amir</dc:creator>
<dc:creator>M Cecilia Bahit</dc:creator>
<dc:creator>Johann Bauersachs</dc:creator>
<dc:creator>Antoni Bayes-Genis</dc:creator>
<dc:creator>Yundai Chen</dc:creator>
<dc:creator>Vijay K Chopra</dc:creator>
<dc:creator>Gemma Figtree</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:creator>Shaun Goodman</dc:creator>
<dc:creator>Nina Gotcheva</dc:creator>
<dc:creator>Shinya Goto</dc:creator>
<dc:creator>Tomasz Gasior</dc:creator>
<dc:creator>Waheed Jamal</dc:creator>
<dc:creator>James L Januzzi</dc:creator>
<dc:creator>Myung Ho Jeong</dc:creator>
<dc:creator>Yuri Lopatin</dc:creator>
<dc:creator>Renato D Lopes</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Puja B Parikh</dc:creator>
<dc:creator>Alexander Parkhomenko</dc:creator>
<dc:creator>Piotr Ponikowski</dc:creator>
<dc:creator>Xavier Rossello</dc:creator>
<dc:creator>Morten Schou</dc:creator>
<dc:creator>Dragan Simic</dc:creator>
<dc:creator>Philippe Gabriel Steg</dc:creator>
<dc:creator>Joanna Szachniewicz</dc:creator>
<dc:creator>Peter van der Meer</dc:creator>
<dc:creator>Dragos Vinereanu</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Martina Brueckmann</dc:creator>
<dc:creator>Mikhail Sumin</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Javed Butler</dc:creator>
<dc:date>2024-04-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights from the EMPACT-MI Trial</dc:title>
<dc:identifier>pmid:38581389</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.069217</dc:identifier>
</item>
<item>
<title>Tracing the origin of alveolar stem cells in lung repair and regeneration</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38579712/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>Alveolar type 2 (AT2) cells are stem cells of the alveolar epithelia. Previous genetic lineage tracing studies reported multiple cellular origins for AT2 cells after injury. However, conventional lineage tracing based on Cre-loxP has the limitation of non-specific labeling. Here, we introduced a dual recombinase-mediated intersectional genetic lineage tracing approach, enabling precise investigation of AT2 cellular origins during lung homeostasis, injury, and repair. We found AT1 cells, being...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 27:S0092-8674(24)00302-7. doi: 10.1016/j.cell.2024.03.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Alveolar type 2 (AT2) cells are stem cells of the alveolar epithelia. Previous genetic lineage tracing studies reported multiple cellular origins for AT2 cells after injury. However, conventional lineage tracing based on Cre-loxP has the limitation of non-specific labeling. Here, we introduced a dual recombinase-mediated intersectional genetic lineage tracing approach, enabling precise investigation of AT2 cellular origins during lung homeostasis, injury, and repair. We found AT1 cells, being terminally differentiated, did not contribute to AT2 cells after lung injury and repair. Distinctive yet simultaneous labeling of club cells, bronchioalveolar stem cells (BASCs), and existing AT2 cells revealed the exact contribution of each to AT2 cells post-injury. Mechanistically, Notch signaling inhibition promotes BASCs but impairs club cells' ability to generate AT2 cells during lung repair. This intersectional genetic lineage tracing strategy with enhanced precision allowed us to elucidate the physiological role of various epithelial cell types in alveolar regeneration following injury.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38579712/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38579712</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.03.010>10.1016/j.cell.2024.03.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38579712</guid>
<pubDate>Fri, 05 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Kuo Liu</dc:creator>
<dc:creator>Xinfeng Meng</dc:creator>
<dc:creator>Zixin Liu</dc:creator>
<dc:creator>Muxue Tang</dc:creator>
<dc:creator>Zan Lv</dc:creator>
<dc:creator>Xiuzhen Huang</dc:creator>
<dc:creator>Hengwei Jin</dc:creator>
<dc:creator>Ximeng Han</dc:creator>
<dc:creator>Xiuxiu Liu</dc:creator>
<dc:creator>Wenjuan Pu</dc:creator>
<dc:creator>Huan Zhu</dc:creator>
<dc:creator>Bin Zhou</dc:creator>
<dc:date>2024-04-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Tracing the origin of alveolar stem cells in lung repair and regeneration</dc:title>
<dc:identifier>pmid:38579712</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.03.010</dc:identifier>
</item>
<item>
<title>Uncovering atherosclerotic cardiovascular disease by PET imaging</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38575752/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>Assessing atherosclerosis severity is essential for precise patient stratification. Specifically, there is a need to identify patients with residual inflammation because these patients remain at high risk of cardiovascular events despite optimal management of cardiovascular risk factors. Molecular imaging techniques, such as PET, can have an essential role in this context. PET imaging can indicate tissue-based disease status, detect early molecular changes and provide whole-body information....</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Apr 4. doi: 10.1038/s41569-024-01009-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Assessing atherosclerosis severity is essential for precise patient stratification. Specifically, there is a need to identify patients with residual inflammation because these patients remain at high risk of cardiovascular events despite optimal management of cardiovascular risk factors. Molecular imaging techniques, such as PET, can have an essential role in this context. PET imaging can indicate tissue-based disease status, detect early molecular changes and provide whole-body information. Advances in molecular biology and bioinformatics continue to help to decipher the complex pathogenesis of atherosclerosis and inform the development of imaging tracers. Concomitant advances in tracer synthesis methods and PET imaging technology provide future possibilities for atherosclerosis imaging. In this Review, we summarize the latest developments in PET imaging techniques and technologies for assessment of atherosclerotic cardiovascular disease and discuss the relationship between imaging readouts and transcriptomics-based plaque phenotyping.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38575752/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38575752</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01009-x>10.1038/s41569-024-01009-x</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38575752</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Alexander Maier</dc:creator>
<dc:creator>Abraham J P Teunissen</dc:creator>
<dc:creator>Sheqouia A Nauta</dc:creator>
<dc:creator>Esther Lutgens</dc:creator>
<dc:creator>Zahi A Fayad</dc:creator>
<dc:creator>Mandy M T van Leent</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Uncovering atherosclerotic cardiovascular disease by PET imaging</dc:title>
<dc:identifier>pmid:38575752</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01009-x</dc:identifier>
</item>
<item>
<title>Infant microbes and metabolites point to childhood neurodevelopmental disorders</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38574728/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>This study has followed a birth cohort for over 20 years to find factors associated with neurodevelopmental disorder (ND) diagnosis. Detailed, early-life longitudinal questionnaires captured infection and antibiotic events, stress, prenatal factors, family history, and more. Biomarkers including cord serum metabolome and lipidome, human leukocyte antigen (HLA) genotype, infant microbiota, and stool metabolome were assessed. Among the 16,440 Swedish children followed across time, 1,197 developed...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Mar 27:S0092-8674(24)00238-1. doi: 10.1016/j.cell.2024.02.035. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">This study has followed a birth cohort for over 20 years to find factors associated with neurodevelopmental disorder (ND) diagnosis. Detailed, early-life longitudinal questionnaires captured infection and antibiotic events, stress, prenatal factors, family history, and more. Biomarkers including cord serum metabolome and lipidome, human leukocyte antigen (HLA) genotype, infant microbiota, and stool metabolome were assessed. Among the 16,440 Swedish children followed across time, 1,197 developed an ND. Significant associations emerged for future ND diagnosis in general and for specific ND subtypes, spanning intellectual disability, speech disorder, attention-deficit/hyperactivity disorder, and autism. This investigation revealed microbiome connections to future diagnosis as well as early emerging mood and gastrointestinal problems. The findings suggest links to immunodysregulation and metabolism, compounded by stress, early-life infection, and antibiotics. The convergence of infant biomarkers and risk factors in this prospective, longitudinal study on a large-scale population establishes a foundation for early-life prediction and intervention in neurodevelopment.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38574728/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38574728</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.02.035>10.1016/j.cell.2024.02.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38574728</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Angelica P Ahrens</dc:creator>
<dc:creator>Tuulia Hyötyläinen</dc:creator>
<dc:creator>Joseph R Petrone</dc:creator>
<dc:creator>Kajsa Igelström</dc:creator>
<dc:creator>Christian D George</dc:creator>
<dc:creator>Timothy J Garrett</dc:creator>
<dc:creator>Matej Orešič</dc:creator>
<dc:creator>Eric W Triplett</dc:creator>
<dc:creator>Johnny Ludvigsson</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Infant microbes and metabolites point to childhood neurodevelopmental disorders</dc:title>
<dc:identifier>pmid:38574728</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.02.035</dc:identifier>
</item>
<item>
<title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38573283/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 13:S0735-1097(24)00473-X. doi: 10.1016/j.jacc.2024.02.034. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38573283/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38573283</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.034>10.1016/j.jacc.2024.02.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38573283</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>B Hadley Wilson</dc:creator>
<dc:creator>Joseph C Wu</dc:creator>
<dc:creator>James C Fang</dc:creator>
<dc:creator>Jodie L Hurwitz</dc:creator>
<dc:creator>George D Dangas</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Modernizing Cardiovascular Medicine Board Certification: Leveraging Innovation and Strengthening Continuous Competency and Professional Growth</dc:title>
<dc:identifier>pmid:38573283</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.034</dc:identifier>
</item>
<item>
<title>Association of Disrupted Delta Wave Activity During Sleep With Long-Term Cardiovascular Disease and Mortality</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38573282/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240408041129&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results suggest that delta wave activity disruption during sleep may be a useful metric to identify those at increased risk for CVD and CVD mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 28:S0735-1097(24)00484-4. doi: 10.1016/j.jacc.2024.02.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Delta wave activity is a prominent feature of deep sleep, which is significantly associated with sleep quality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The authors hypothesized that delta wave activity disruption during sleep could predict long-term cardiovascular disease (CVD) and CVD mortality risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We used a comprehensive power spectral entropy-based method to assess delta wave activity during sleep based on overnight polysomnograms in 4,058 participants in the SHHS (Sleep Heart Health Study) and 2,193 participants in the MrOS (Osteoporotic Fractures in Men Study) Sleep study.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 11.0 ± 2.8 years of follow-up in SHHS, 729 participants had incident CVD and 192 participants died due to CVD. During 15.5 ± 4.4 years of follow-up in MrOS, 547 participants had incident CVD, and 391 died due to CVD. In multivariable Cox regression models, lower delta wave entropy during sleep was associated with higher risk of coronary heart disease (SHHS: HR: 1.46; 95% CI: 1.02-2.06; P = 0.03; MrOS: HR: 1.79; 95% CI: 1.17-2.73; P &lt; 0.01), CVD (SHHS: HR: 1.60; 95% CI: 1.21-2.11; P &lt; 0.01; MrOS: HR: 1.43; 95% CI: 1.00-2.05; P = 0.05), and CVD mortality (SHHS: HR: 1.94; 95% CI: 1.18-3.18; P &lt; 0.01; MrOS: HR: 1.66; 95% CI: 1.12-2.47; P = 0.01) after adjusting for covariates. The Shapley Additive Explanations method indicates that low delta wave entropy was more predictive of coronary heart disease, CVD, and CVD mortality risks than conventional sleep parameters.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results suggest that delta wave activity disruption during sleep may be a useful metric to identify those at increased risk for CVD and CVD mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38573282/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240408041129&v=2.18.0.post9+e462414">38573282</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.02.040>10.1016/j.jacc.2024.02.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38573282</guid>
<pubDate>Thu, 04 Apr 2024 06:00:00 -0400</pubDate>
<dc:creator>Sizhi Ai</dc:creator>
<dc:creator>Shuo Ye</dc:creator>
<dc:creator>Guohua Li</dc:creator>
<dc:creator>Yue Leng</dc:creator>
<dc:creator>Katie L Stone</dc:creator>
<dc:creator>Min Zhang</dc:creator>
<dc:creator>Yun-Kwok Wing</dc:creator>
<dc:creator>Jihui Zhang</dc:creator>
<dc:creator>Yannis Yan Liang</dc:creator>
<dc:date>2024-04-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Disrupted Delta Wave Activity During Sleep With Long-Term Cardiovascular Disease and Mortality</dc:title>
<dc:identifier>pmid:38573282</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.02.040</dc:identifier>
</item>





























</channel>
</rss>